Guardant Complete Guardant Complete

Testing Across the Continuum of Cancer


A Fast CGP Panel with Guideline-Recommended Actionable Biomarkers

Our Guardant360 CDx test is our FDA-approved liquid biopsy that provides results in 7 days upon sample receipt in the laboratory to inform treatment decisions.1 

Lab technician handles a blood vial.

Liquid Comprehensive Genomic Profiling with an Expanded Panel of Biomarkers

The Guardant360 liquid biopsy test helps find additional treatment options with an expanded panel of biomarkers.

The Only Tissue Comprehensive Genomic Profiling with AI-powered PD-L1 Detection

Our Guardant360 TissueNext tissue biopsy test finds actionable information when tissue testing is appropriate. The test leverages our AI-powered TPS analyser to improve PD-L1 detection by >20% in NSCLC.2,3

The only tissue comprehensive genomic profiling with AI-powered PD-L1 detection

Our Guardant360 TissueNext tissue biopsy test finds actionable information when tissue testing is appropriate. The test leverages our AI-powered scoring algorithm to improve PD-L1 detection by >20% in NSCLC.1,2 * Guardant360 TissueNext has broad commercial and Medicare coverage for advanced solid tumors.

*compared to manual pathologist interpretation in the most challenging cases in NSCLC
  • Guardant360 TissueNext Assay Specifications. Guardant Health Inc. Redwood City, CA.
  • Data on file. Guardant Health, Inc. Redwood City, CA.
Guardant Reveal Box

Minimal Residual Disease Detection and Recurrence Monitoring

Guardant Reveal is a blood-only test without tissue baseline that detects circulating tumor DNA (ctDNA) for minimal residual disease (MRD) assessment in early-stage colorectal, breast, and lung cancers. In addition to detection of MRD, Guardant Reveal is also available to monitor recurrence in previously diagnosed patients.

The Only Tissue-Free Biopsy to Measure Treatment Response

Our Guardant360 Response test is the first tissue-free biopsy that enables doctors to view molecular response, or changes in circulating tumor DNA (ctDNA) levels, to get an early indication of patient response to immunotherapy or targeted therapy for advanced stage solid tumors. Studies show the Guardant360 Response test can predict treatment response 8 weeks earlier than current standard-of-care imaging.4-13


Request a Test Kit

Contact us to order a test kit.

Contact Us